Business Description
Oryzon Genomics SA
ISIN : ES0167733015
Total Employee Number:
44Description
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.87 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.65 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 12.8 | |||||
3-Year EPS without NRI Growth Rate | 23.6 | |||||
3-Year FCF Growth Rate | 15.9 | |||||
3-Year Book Growth Rate | 5.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -263.03 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.89 | |||||
9-Day RSI | 53.68 | |||||
14-Day RSI | 68.08 | |||||
3-1 Month Momentum % | 10.78 | |||||
6-1 Month Momentum % | 10.12 | |||||
12-1 Month Momentum % | 14.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.4 | |||||
Shareholder Yield % | 0.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1.74 | |||||
ROA % | -1.42 | |||||
ROIC % | -3.7 | |||||
3-Year ROIIC % | 2.72 | |||||
ROC (Joel Greenblatt) % | -3396.29 | |||||
ROCE % | -9.14 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 520.72 | |||||
PB Ratio | 2.07 | |||||
Price-to-Tangible-Book | 2.06 | |||||
EV-to-EBIT | -18.66 | |||||
EV-to-Forward-EBIT | -30.02 | |||||
EV-to-EBITDA | -18.76 | |||||
EV-to-Forward-EBITDA | -30.51 | |||||
EV-to-Forward-Revenue | 29.25 | |||||
EV-to-FCF | -16.51 | |||||
Earnings Yield (Greenblatt) % | -5.36 | |||||
FCF Yield % | -5.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ORYZF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oryzon Genomics SA Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.025 | ||
| Beta | -0.5543 | ||
| 3-Year Sharpe Ratio | 0.4 | ||
| 3-Year Sortino Ratio | 0.92 | ||
| Volatility % | 18.89 | ||
| 14-Day RSI | 68.08 | ||
| 14-Day ATR ($) | 0.006598 | ||
| 20-Day SMA ($) | 3.6725 | ||
| 12-1 Month Momentum % | 14.79 | ||
| 52-Week Range ($) | 3.2233 - 4.375 | ||
| Shares Outstanding (Mil) | 77.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oryzon Genomics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oryzon Genomics SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 35 days | ||
| General meeting for 2026 | 2026-06-26 | In 1 day | ||
| First quarter earnings results for 2026 | 2026-05-14 | 3.34 (+0.00%) | ||
| Annual report for 2025 | 2026-02-27 | 3.60 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-27 | 3.60 (+0.00%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-12 | 3.36 (+0.00%) | ||
| 9th Sachs Annual Neuroscience Innovation Forum | 2026-01-11 10:35 | 3.36 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 3.61 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-07-30 | 3.28 (+0.00%) |
Show
Entries
Oryzon Genomics SA Frequently Asked Questions
What is Oryzon Genomics SA(ORYZF)'s stock price today?
The current price of ORYZF is $3.65. The 52 week high of ORYZF is $4.38 and 52 week low is $3.22.
When is next earnings date of Oryzon Genomics SA(ORYZF)?
The next earnings date of Oryzon Genomics SA(ORYZF) is 2026-07-30 Est..
Does Oryzon Genomics SA(ORYZF) pay dividends? If so, how much?
Oryzon Genomics SA(ORYZF) does not pay dividend.
Guru Commentaries on OTCPK:ORYZF
No articles.
Articles on Oryzon Genomics SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers